Nucleostemin promotes the proliferation of human glioma via Wnt/β-Catenin pathway
Corresponding Author
Zhen Bao
Departments of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China
Correspondence: Gang Cui, Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China. Email: [email protected]Search for more papers by this authorYunfeng Wang
Departments of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China
Search for more papers by this authorLixiang Yang
Departments of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China
Search for more papers by this authorLin Wang
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China
Search for more papers by this authorLianxin Zhu
Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province, People's Republic of China
Search for more papers by this authorNa Ban
Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province, People's Republic of China
Search for more papers by this authorShaochen Fan
Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province, People's Republic of China
Search for more papers by this authorWenjuan Chen
Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province, People's Republic of China
Search for more papers by this authorJie Sun
Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province, People's Republic of China
Search for more papers by this authorChaoyan Shen
Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province, People's Republic of China
Search for more papers by this authorGang Cui
Departments of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China
Search for more papers by this authorCorresponding Author
Zhen Bao
Departments of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China
Correspondence: Gang Cui, Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China. Email: [email protected]Search for more papers by this authorYunfeng Wang
Departments of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China
Search for more papers by this authorLixiang Yang
Departments of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China
Search for more papers by this authorLin Wang
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China
Search for more papers by this authorLianxin Zhu
Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province, People's Republic of China
Search for more papers by this authorNa Ban
Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province, People's Republic of China
Search for more papers by this authorShaochen Fan
Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province, People's Republic of China
Search for more papers by this authorWenjuan Chen
Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province, People's Republic of China
Search for more papers by this authorJie Sun
Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province, People's Republic of China
Search for more papers by this authorChaoyan Shen
Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province, People's Republic of China
Search for more papers by this authorGang Cui
Departments of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China
Search for more papers by this authorAbstract
Nucleostemin, nucleolar guanosine triphosphate (GTP)-binding protein 3, is a member of the MMR1/HSR1 GTP-binding protein family. The important roles of nucleostemin in self-renewal, cell cycle regulation, apoptosis, and cell proliferation of various cancer types as been shown. Nevertheless, its expression and potential functions in human glioma is still unclear. In the present study, we demonstrated that up-regulation of nucleostemin was tightly related to poor 5-year-survival ratios. In serum-starved and re-feeding models of U251 and U373MG, we observed the rising expression of nucleostemin and p-β-Catenin (p-Tyr645) were accompanied with cell proliferation markers (cyclin D1 and proliferating cell nuclear antigen (PCNA)). Employing nucleostemin-depletion models, we found down-regulated nucleostemin and p-β-Catenin. The flow cytometry analysis proved the weakened cell proliferation. Moreover, we detected the translocation of β-Catenin into the nucleus was impaired, meaning the inhibition of the Wnt/β-Catenin pathway. Taken together, we identified a positive correlation between up-regulation of nucleostemin and human glioma cell proliferation and that knocking-down nucleostemin alleviated glioma proliferation by reducing β-Catenin transportation into the nucleus. All results suggested that nucleostemin might accelerate human glioma proliferation via the Wnt/β-Catenin pathway.
References
- 1Deorah S, Lynch CF, Sibenaller ZA, Ryken TC. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus 2006; 20: E1.
- 2Reardon DA, Herndon JE 2nd, Peters KB et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer 2012; 107: 1481–1487.
- 3Bertling E, Hotulainen P, Mattila PK, Matilainen T, Salminen M, Lappalainen P. Cyclase-associated protein 1 (CAP1) promotes cofilin-induced actin dynamics in mammalian nonmuscle cells. Mol Biol Cell 2004; 15: 2324–2334.
- 4Maher EA, Furnari FB, Bachoo RM et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001; 15: 1311–1333.
- 5Zhuang W, Qin Z, Liang Z. The role of autophagy in sensitizing malignant glioma cells to radiation therapy. Acta Biochim Biophys Sin 2009; 41: 341–351.
- 6Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci 2005; 1056: 218–233.
- 7Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492–507.
- 8Tsai RY, McKay RD. A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes Dev 2002; 16: 2991–3003.
- 9Ma H, Pederson T. Depletion of the nucleolar protein nucleostemin causes G1 cell cycle arrest via the p53 pathway. Mol Biol Cell 2007; 18: 2630–2635.
- 10Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983–3988.
- 11Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946–10951.
- 12Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328–9337.
- 13Szotek PP, Pieretti-Vanmarcke R, Masiakos PT et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A 2006; 103: 11154–11159.
- 14Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104: 973–978.
- 15O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106–110.
- 16Li C, Lee CJ, Simeone DM. Identification of human pancreatic cancer stem cells. Methods Mol Biol 2009; 568: 161–173.
- 17Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504–514.
- 18Kobayashi T, Masutomi K, Tamura K et al. Nucleostemin expression in invasive breast cancer. BMC Cancer 2014; 14: 215.
- 19Bernardi R, Pandolfi PP. The nucleolus: at the stem of immortality. Nat Med 2003; 9: 24–25.
- 20Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837–1851.
- 21Cho IR, Koh SS, Min HJ et al. Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the expression of beta-catenin, leading to a rapid proliferation of pancreatic cells. Exp Mol Med 2011; 43: 82–90.
- 22Fernandez-Sanchez ME, Barbier S, Whitehead J et al. Mechanical induction of the tumorigenic beta-catenin pathway by tumour growth pressure. Nature 2015; 523: 92–95.
- 23He TC, Sparks AB, Rago C et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509–1512.
- 24He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335–345.
- 25Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422–426.
- 26Gil-Ranedo J, Mendiburu-Elicabe M, Garcia-Villanueva M, Medina D, del Alamo M, Izquierdo M. An off-target nucleostemin RNAi inhibits growth in human glioblastoma-derived cancer stem cells. PLoS One 2011; 6: e28753.
- 27Ding Z, Liu X, Liu Y et al. Expression of far upstream element (FUSE) binding protein 1 in human glioma is correlated with c-Myc and cell proliferation. Mol Carcinog 2015; 54: 405–415.
- 28Lin SY, Makino K, Xia W et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3: 802–808.
- 29Giri DK, Ali-Seyed M, Li LY et al. Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol 2005; 25: 11005–11018.
- 30Ferguson SD. Malignant gliomas: diagnosis and treatment. Disease-a-month : DM 2011; 57: 558–569.
- 31Stupp R, Hegi ME, van den Bent MJ et al. Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist 2006; 11: 165–180.
- 32Qi S, Song Y, Peng Y et al. ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS One 2012; 7: e38842.
- 33Radner H, Blumcke I, Reifenberger G, Wiestler OD. The new WHO classification of tumors of the nervous system 2000. Pathology and genetics. Pathologe 2002; 23: 260–283.
- 34van Noort M, Meeldijk J, van der Zee R, Destree O, Clevers H. Wnt signaling controls the phosphorylation status of beta-catenin. J Biol Chem 2002; 277: 17901–17905.
- 35Larriba MJ, Gonzalez-Sancho JM, Barbachano A, Niell N, Ferrer-Mayorga G, Munoz A. Vitamin D Is a Multilevel Repressor of Wnt/b-Catenin Signaling in Cancer Cells. Cancers 2013; 5: 1242–1260.
- 36Cadigan KM, Waterman ML. TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb Perspect Biol 2012; 4(11) pii: a007906.
- 37Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149: 1192–1205.
Citing Literature
